Drug Trial Radar · NCT04692181
SYN-004 Safety and Tolerability in Allo-HCT Subjects
Last checked: Nov 19, 2026Latest source record: Mar 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Feb 15, 2021
Primary completion
Sep 30, 2029
Study completion Sep 30, 2030
Sponsor
- Lead sponsor
- Theriva Biologics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Washington University School of Medicine
- First posted
- Dec 31, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study Objectives: 1. To evaluate the safety and tolerability of oral SYN-004 in adult allogeneic HCT (allo-HCT) recipients who develop fever after conditioning therapy and are treated with IV β-lactam antibiotics meropenem (MER), piperacillin tazobactam (PIP/TAZO), or cefepime (FEP). 2. To evaluate potential absorption of oral SYN-004 into the systemic circulation of allo-HCT recipients and potential SYN-004-mediated alterations to systemic levels and efficacy of IV MER, PIP/TAZO or FEP. 3. To evaluate potential protective effects of SYN-004 on the intestinal microbiome of allo-HCT recipients treated with IV MER, PIP/TAZO or FEP. 4. To obtain preliminary information on potential therapeutic benefits and patient outcomes of SYN-004 in allo-HCT recipients treated with IV MER, PIP/TAZO or FEP
Conditions
- Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant
- Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam Antibiotics
Interventions
SYN-004, Ribaxamase or PlaceboBiological
SYN-004 is an oral formulation of a recombinant class-A beta-lactamase that hydrolyzes the beta-lactam ring of susceptible antibiotics that are excreted into the intestines
Primary outcomes
What the sponsor says the trial is designed to measure.
- SYN-004 systemic absorptionTime frame: No more than 28 days
- Systemic antibiotic concentrationsTime frame: Up to 8 hours after IV administration of antibiotic
- BacteremiaTime frame: Daily during treatment, and weekly until 30 days after discontinuation of SYN-004 or Placebo
- Bacterial intestinal infectionsTime frame: Daily during treatment, and weekly until 30 days after discontinuation of SYN-004 or Placebo
- Grade 3 or 4 adverse eventsTime frame: Up to 30 days after the last dose of SYN-004 or Placebo
- Overall survivalTime frame: Up to 30 days after the last dose of SYN-004 or Placebo
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Washington University
St Louis, Missouri
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.